A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma
NCT06296121
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
252
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
BCD-264
DRUG:
Darzalex
Sponsor
Biocad